



3<sup>rd</sup> November 2022

The Manager,  
Listing Compliance Department,  
**National Stock Exchange of India Ltd,**  
Exchange Plaza, Bandra Kurla Complex,  
Bandra (East), Mumbai – 400051

Corporate Office :  
406, Silver Oaks Comm. Complex,  
Opp. Arun Society, Paldi,  
Ahmedabad-380 007. Gujarat, India.  
Phone : 079-26584655  
Fax : 079-26588054  
CIN No. : L24231GJ2004PLC043861  
E-mail : info@sakarhealthcare.com  
Web : www.sakarhealthcare.com

Symbol: SAKAR

**Subject: Announcement under Regulation 30 (LODR)**  
**Sakar Healthcare progressed with API in oncology segment**

Dear All,

Sakar Healthcare is happy to share that Active Pharmaceutical Ingredient (API) manufacturing unit a part of its research-driven API-integrated oncology formulation manufacturing unit located at Bavla, Gujarat, India has become fully operational with approval by WHO GMP.

The API plant has been suitably equipped with containment technology, controls and capabilities for safe manufacturing and handling of highly-potent APIs (HPAPI). The manufacturing capacity of Pilot area ranges from 1.00 Kg to 10.00 Kg whereas, for Intermediate area it is 25kg to 80 kgs. The Gram scale area has fume hood, bio-safety cabinet, glass assembly, chromatographic column & rotavapour and meant for batch sizes between 10 gm to 500 gm. The Finished area is for crystallisation, filtration, drying milling sifting, jet milling, sampling, final packing. All 11-glass-line reactors are from renowned company of international repute in the cytotoxic domain and uses negative pressure isolator for drying in a close loop. Thus the EU GMP compliant API manufacturing unit is offering:

- Phase-wise scale up studies with impurity profiling, stability studies, risk analysis studies and production from gram scale to kilo scale with all cGMP documentation in HPAPI containment area
- Pilot plant validation for technology transfer with subsequent scale up for Intermediates, HPAPIs in contained lines
- Process validation with complete PDR as per QBD concept for development products

Presently Sakar Healthcare has completed process validation for five anti-cancer molecules with process completion from R&D to Gram to Pilot to Commercial scale for three products. The KSM vendor assessments with necessary audits have been completed. Some of the tests have been done through external agencies to confirm same are in-line to in-house results.

This API manufacturing unit has manifold benefits to Sakar Healthcare:

- In-house API supply for own finished formulations:
  - ensuring readiness in availability
  - favoring better margins
- Revenues from APIs produced apart from captive use: adding to top-line values
- Allowing backward integration for partner business (CMO)- widening business opportunity

This is for your information, records and meeting the disclosure requirements under the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended from time to time.

Thanking you,

Yours faithfully,  
for **SAKAR HEALTHCARE LIMITED**

**BHARAT SONI**  
**COMPANY SECRETARY &**  
**COMPLIANCE OFFICER**